BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and…
- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs…